e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Pulmonary hypertension: novelties from the bench
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Survivin inhibition as a potential target for pulmonary arterial hypertension
I. Blanco (Barcelona, Spain), M. Marquina (Barcelona, Spain), O. Tura-Ceide (Barcelona, Spain), V. Peinado (Barcelona, Spain), J. Barberà (Barcelona, Spain)
Source:
International Congress 2019 – Pulmonary hypertension: novelties from the bench
Session:
Pulmonary hypertension: novelties from the bench
Session type:
Poster Discussion
Number:
5055
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Blanco (Barcelona, Spain), M. Marquina (Barcelona, Spain), O. Tura-Ceide (Barcelona, Spain), V. Peinado (Barcelona, Spain), J. Barberà (Barcelona, Spain). Survivin inhibition as a potential target for pulmonary arterial hypertension. 5055
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension
Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020
Year: 2020
Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension
Year: 2007
Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target
Source: Eur Respir J 2011; 38: 1453-1460
Year: 2011
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 147s
Year: 2006
Targeting cell motility in pulmonary arterial hypertension
Source: Eur Respir J 2014; 43: 531-544
Year: 2013
Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension
Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019
Year: 2021
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy
Source: Eur Respir J 2006; 28: Suppl. 50, 159s
Year: 2006
Targeting BMPR-II in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches
Year: 2016
Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension
Source: Eur Respir J 2010; 36: 1483-1485
Year: 2010
The pathophysiological role of novel pulmonary arterial hypertension gene
SOX17
Source: Eur Respir J, 58 (3) 2004172; 10.1183/13993003.04172-2020
Year: 2021
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition
Source: Eur Respir J 2013; 42: 869-870
Year: 2013
Towards an understanding of pulmonary arterial hypertension (PAH): gene regulation patterns in pulmonary arterial resistance vessels of patients with PAH
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006
CFTR involvement in the pathogenesis of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Multi-omic profiling in pulmonary arterial hypertension
Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension
Year: 2020
The future of treatment for pulmonary arterial hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
The future of treatment for pulmonary arterial hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012
The future of treatment for pulmonary arterial hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
The future of treatment for pulmonary arterial hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept